iRhythm/$IRTC
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About iRhythm
iRhythm Holdings Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.
- Ticker
- $IRTC
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 2,400
- Headquarters
- San Francisco, United States
- Website
- www.irhythmtech.com
iRhythm Metrics
BasicAdvanced
$3.5B
-
-$0.43
1.32
-
Price and volume
Market cap
$3.5B
Beta
1.32
52-week high
$212.00
52-week low
$100.85
Average daily volume
513K
Financial strength
Current ratio
3.855
Quick ratio
3.445
Long term debt to equity
3.82
Total debt to equity
3.911
Interest coverage (TTM)
0.81%
Profitability
EBITDA (TTM)
17.695
Gross margin (TTM)
71.45%
Net profit margin (TTM)
-1.69%
Operating margin (TTM)
1.30%
Effective tax rate (TTM)
-7.48%
Revenue per employee (TTM)
$340,000
Management effectiveness
Return on assets (TTM)
0.65%
Return on equity (TTM)
-9.63%
Valuation
Price to revenue (TTM)
4.129
Price to book
18.6
Price to tangible book (TTM)
18.68
Price to free cash flow (TTM)
87.432
Free cash flow yield (TTM)
1.14%
Free cash flow per share (TTM)
1.201
Growth
Revenue change (TTM)
25.58%
Earnings per share change (TTM)
-85.34%
3-year revenue growth (CAGR)
22.22%
10-year revenue growth (CAGR)
32.69%
3-year earnings per share growth (CAGR)
-49.21%
10-year earnings per share growth (CAGR)
-30.75%
What the Analysts think about iRhythm
Analyst ratings (Buy, Hold, Sell) for iRhythm stock.
Analyst projections of the future price of iRhythm stock.
Bulls say / Bears say
iRhythm is still delivering unusually strong growth: second-quarter revenue rose 20.1%, marking its seventh consecutive quarter above 20%, while full-year 2026 revenue guidance was raised to $880m-$890m. Gross margin reached 72.8% and adjusted EBITDA margin 19.3%, showing that scale is improving profitability as well as sales. (GlobeNewswire)
The FDA has cleared iRhythm’s third-generation algorithm, which the company plans to deploy across its platform in the first half of 2027. Management expects it to cut technician review time by up to 50% and generate about $100m of cumulative cost savings over five years, creating a potential margin lever as volumes grow. (Longbridge, StockAnalysis)
The planned $287.5m VitalConnect acquisition would broaden iRhythm beyond Zio into mobile cardiac telemetry, multi-vitals and hospital-to-home monitoring. The US antitrust waiting period has expired, reducing a key closing risk, and iRhythm can use its much larger sales force to accelerate VitalConnect’s distribution. (MassDevice, StockTitan)
iRhythm remains subject to an FDA warning letter, and the timing of the agency’s review and any closing action is outside the company’s control. This leaves a regulatory overhang even though management says remediation and an independent review have been completed. (The Motley Fool, StockAnalysis)
Reimbursement remains a risk to expansion, particularly outside the US: European frameworks are fragmented and Japan currently reimburses Zio at rates comparable with traditional Holter monitoring. That could limit pricing and slow adoption unless iRhythm proves superior outcomes in each market. (Yahoo Finance)
VitalConnect adds execution and capital-allocation risk before it adds meaningful growth: iRhythm is paying about $287.5m, including $237.5m in cash, while integration and the national rollout depend on retaining customers and successfully scaling in a competitive MCT market. iRhythm’s own Zio MCT launch is also targeted only for the first half of 2027. (MassDevice, StockAnalysis)
Data summarised monthly by Lightyear AI. Last updated on 26 Sept 2026.
iRhythm Financial Performance
Revenues and expenses
iRhythm Earnings Performance
Company profitability
Upcoming events
No upcoming events
iRhythm News
AllArticlesVideos
Funds containing iRhythm
AllEURGBPUSD
Fund name | Fund size | $IRTC weighting |
|---|---|---|
iShares Ageing Population€AGED | €822M | 0.31% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.12% |
SPDR Russell 2000 US Small Cap£R2SC | £4.1B | 0.12% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.05% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | £2.4B | 0.05% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.